Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

ABSTRACT:

Objective

The current study examined the efficacy and safety of rasagiline, a selective MAO-B inhibitor, for the treatment of persistent negative symptoms.

Methods

Sixty people with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, schizophrenia or schizoaffective disorder, who met a priori criteria for persistent negative symptoms, were randomized to receive rasagiline, 1mg/d (n = 31) or placebo (n = 29) in a 12-week, double-blind, placebo-controlled clinical trial. The Scale for the Assessment of Negative Symptoms (SANS) total score was used to assess change in negative symptoms. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), N-Back test, a probabilistic learning task, and a delayed discounting task were used to assess

SUBMITTER: Buchanan RW 

PROVIDER: S-EPMC4466175 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature